Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- Conditions
- Solid Tumors
- Interventions
- Registration Number
- NCT04589845
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 920
- Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy
- Measurable disease as defined by RECIST v1.1, RANO, or INRC
- Performance status as follows: Participants aged ≥ 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to < 18 years: Karnofsky score ≥ 50%; Participants aged < 16 years: Lansky score ≥ 50%
- For participants aged ≥ 18 and < 18 years: adequate hematologic and end-organ function
- Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
- Adequate recovery from most recent systemic or local treatment for cancer
- Life expectancy ≥ 8 weeks
- Ability to comply with the study protocol, in the investigator's judgment
- For female participants of childbearing potential: Negative serum pregnancy test ≤ 14 days prior to initiating study treatment, agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period
- For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria
- In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort
- Current participation or enrollment in another therapeutic clinical trial
- Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
- Whole brain radiotherapy within 14 days prior to start of study treatment
- Stereotactic radiosurgery within 7 days prior to start of study treatment
- Pregnant or breastfeeding, or intending to become pregnant during the study
- History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
- Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
- History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
- In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort A: ROS Proto-oncogene 1 (ROS1) Fusion-positive Tumors (Excluding NSCLC) Entrectinib Participants with metastatic or advanced solid tumors, with the exception of non-small cell lung cancer (NSCLC), will receive entrectinib once daily (QD) in repeated 28-day cycles at a dose of 600 milligram per day (mg/day) for adults and pediatric participants with a body surface area (BSA) ≥ 1.51 square meter (m\^2). The total dose of daily entrectinib administration for pediatric participants with BSA \< 1.51 m\^2 will be lower. Cohort B: Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Fusion-positive Tumors Entrectinib Participants with metastatic or advanced solid tumors will receive entrectinib, QD in repeated 28-day cycles at a dose of 600 mg/day for adults and pediatric participants with a BSA ≥ 1.51 m\^2. The total dose of daily entrectinib administration for pediatric participants with BSA \< 1.51 m\^2 will be lower. Cohort C: Anaplastic Lymphoma Kinase (ALK) Fusion-positive Tumors (Excluding NSCLC) Alectinib Participants with metastatic or advanced solid tumors, with the exception of NSCLC, will receive alectinib at a dosage of 600 mg, orally, twice a day (BID), taken with food, in repeated 28-day cycles. Cohort K: Rearranged During Transfection (RET) Fusion-positive Tumors (Excluding NSCLC) Pralsetinib Participants with RET fusion-positive tumors will self-administer pralsetinib orally at home (except on clinic days) on a continuous daily dosing regimen at a dose of 400 mg/day (four 100-mg capsules per day) for adult and pediatric participants ≥ 12 and \< 18 years of age. A treatment cycle consists of 4 weeks (28 days). Note: Cohort K has been closed for enrollment. Cohort N: SETD2 LOF Tumors Camonsertib Participants with methyltransferase SET (Su(var) 3-9) Enhancer of zest and Trithorax) domain-containing 2 (SETD2) LOF tumors will self-administer camonsertib orally at home (except on clinic days). Cohort D: TMB-high Tumors Atezolizumab Participants with metastatic or advanced solid tumors will receive atezolizumab intravenously (IV) at a fixed dose for participants aged ≥ 18 years, and 15 milligrams per kilogram (mg/kg) (maximum 1200 mg) for participants aged \< 18 years on Day 1 of each 21-day cycle. Note: Cohort D has been closed for enrollment. Cohort E: Protein Kinase B (AKT) 1/2/3 Mutant-positive Tumors Ipatasertib Participants with metastatic or advanced solid tumors will receive ipatasertib orally, QD at the starting dose of 400 mg in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. For participants 12-17 years of age, ipatasertib will be administered at the starting dose of 200 mg for participants \< 35 kilograms (kg), 300 mg for participants ≥ 35 and \< 45 kg, 400 mg for those ≥ 45 kg orally QD in repeated 28-day cycles until the participant experiences disease progression, intolerable toxicity, or withdraws consent. Note: Cohort E has been closed for enrollment. Cohort F: Human Epidermal Growth Factor Receptor 2 (HER2) Mutant-positive Tumors Trastuzumab emtansine Participants with metastatic or advanced solid tumors will receive trastuzumab emtansine IV at a dose of 3.6 mg/kg every 21 days. Note: Cohort F has been closed as of protocol version 7 because enrollment and participant follow-up have been completed. Cohort H: PIK3CA Multiple Mutant-positive Tumors Inavolisib Participants with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) multiple mutant-positive tumors will receive inavolisib (GDC-0077) QD at a starting dose of 9 mg by mouth (PO) in repeated 28-day cycles. Note: Cohort H has been closed for enrollment. Cohort I: BRAF Class II Mutant or Fusion-positive Tumors Belvarafenib Participants with proto-oncogene B-Raf (BRAF) class II mutant/fusion-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib, PO, BID with adequate water (more than 200 milliliters \[mL\]). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort I has been closed for enrollment. Cohort J: BRAF Class III Mutant-positive Tumors Belvarafenib Participants with BRAF class III mutant-positive tumors (adults and adolescents ≥ 40 kg) will receive 400 mg belvarafenib PO BID with adequate water (more than 200 mL). One cycle consists of 28 days. Administration of belvarafenib should occur BID on every day of each 28-day cycle. Note: Cohort J has been closed for enrollment. Cohort L: KRAS G12C-positive Tumors (Excluding NSCLC and Colorectal Cancer [CRC]) Divarasib Participants with kirsten rat sarcoma virus (KRAS) G12C-positive tumors will self-administer divarasib (GDC-6036) orally at home (except on clinic days). Cohort M: Ataxia-telangiectasia Mutated (ATM) Loss of Function (LOF) Tumors Camonsertib Participants with ATM LOF tumors will self-administer camonsertib orally at home (except on clinic days).
- Primary Outcome Measures
Name Time Method All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) Approximately up to 12 years Confirmed objective response indicates ≥4 weeks after initial documentation of response.
- Secondary Outcome Measures
Name Time Method All Cohorts: IRC-assessed Duration of Response (DOR) per RECIST v1.1 Approximately up to 12 years All Cohorts: IRC-assessed Clinical Benefit Rate (CBR) per RECIST v1.1 Approximately up to 12 years All Cohorts: IRC-assessed Progression-free Survival (PFS) per RECIST v1.1 Approximately up to 12 years All Cohorts: Investigator (INV)-assessed ORR per RECIST v1.1 Approximately up to 12 years All Cohorts: INV-assessed DOR per RECIST v1.1 Approximately up to 12 years All Cohorts: INV-assessed CBR per RECIST v1.1 Approximately up to 12 years All Cohorts: INV-assessed PFS per RECIST v1.1 Approximately up to 12 years All Cohorts: IRC- and INV-assessed Time to Central Nervous System (CNS) Progression per RECIST v1.1 Approximately up to 12 years All Cohorts: Overall Survival (OS) Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-ORR per Response Assessment in Neuro-oncology (RANO) Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-DOR per RANO Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-CBR per RANO Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed CNS-PFS per RANO Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed CNS-ORR per RANO Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed CNS-DOR per RANO Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed CNS-CBR per RANO Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed CNS-PFS per RANO Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed ORR per International Neuroblastoma Response Criteria (INRC) Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed DOR per INRC Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed CBR per INRC Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: IRC-assessed PFS per INRC Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed ORR per INRC Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed DOR per INRC Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed CBR per INRC Approximately up to 12 years Cohorts A, B, C, D, E, F, H, I, J, K, L, M, N: INV-assessed PFS per INRC Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed Intracranial (IC)-ORR per RECIST v1.1 Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed IC-DOR per RECIST v1.1 Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed IC-CBR per RECIST v1.1 Approximately up to 12 years Cohorts A, B, C, D, I, J, K: IRC-assessed IC-PFS Rate per RECIST v1.1 Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed IC-ORR per RECIST v1.1 Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed IC-DOR per RECIST v1.1 Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed IC-CBR per RECIST v1.1 Approximately up to 12 years Cohorts A, B, C, D, I, J, K: INV-assessed IC-PFS Rate per RECIST v1.1 Approximately up to 12 years Cohorts A and B: Percentage of Participants With Confirmed Deterioration as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Approximately up to 12 years The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.
Cohorts A and B: Change From Baseline in the EORTC-QLQ-C30 Total Score Approximately up to 12 years The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.
Cohorts A and B: Percentage of Participants With a Clinical Meaningful Change on the Global Health Status, Physical Functioning, and Role Functioning Scores From the EORTC QLQ-C30 Approximately up to 12 years The EORTC QLQ-C30 is a validated, reliable self-report measure. It consists of 30 questions that assess five aspects of participant functioning (physical, emotional, role, cognitive, and social), eight symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea) and global health/quality of life, with a recall period of the previous week. Scale scores can be obtained for the multi-item scales using rating scales of 4 or 7 points.
Cohorts A and B: Time to Confirmed Symptom Onset or Worsening From Tumor-related Symptom Scores From the EORTC QLQ-C30 and EORTC Item Library 71 (IL71) Approximately up to 12 years The EORTC Item library includes stand-alone symptoms scales and an overall assessment of treatment bother to provide additional information not currently captured in the EORTC QLQ-C30. The scales use the same rating scale and recall period of previous week as the symptom scales in the EORTC QLQ-C30.
All Cohorts: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Approximately up to 12 years AE severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE v5.0.)
Trial Locations
- Locations (162)
GHdC Site Les Viviers
🇧🇪Charleroi, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
Jilin Cancer Hospital
🇨🇳Changchun, China
West China Hospital - Sichuan University
🇨🇳Chengdu City, China
Shanghai East Hospital
🇨🇳Shanghai City, China
Uniklinikum, Comprehensive Cancer Center Mainfranken
🇩🇪Würzburg, Germany
Southern Cancer Center
🇺🇸Daphne, Alabama, United States
Western Regional Medical Center at Cancer Treatment Centers of America
🇺🇸Goodyear, Arizona, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
Kaiser Permanente Los Angeles
🇺🇸Los Angeles, California, United States
USC Norris Cancer Center
🇺🇸Los Angeles, California, United States
Hoag Memorial Hospital
🇺🇸Newport Beach, California, United States
UC Davis Comprehensive Cancer Center
🇺🇸Sacramento, California, United States
University of California at San Francisco
🇺🇸San Francisco, California, United States
Sarcoma Oncology Center
🇺🇸Santa Monica, California, United States
Children's Hospital Colorado
🇺🇸Aurora, Colorado, United States
Christiana Care Health Srvcs
🇺🇸Newark, Delaware, United States
University of Florida
🇺🇸Gainesville, Florida, United States
Miami Cancer Institute of Baptist Health, Inc.
🇺🇸Miami, Florida, United States
Ocala Oncology Center
🇺🇸Ocala, Florida, United States
University Cancer & Blood Center, LLC
🇺🇸Athens, Georgia, United States
St. Alphonsus
🇺🇸Boise, Idaho, United States
Midwestern Regional Med Center
🇺🇸Zion, Illinois, United States
Horizon Oncology Research, Inc.
🇺🇸Lafayette, Indiana, United States
New England Cancer Specialists
🇺🇸Scarborough, Maine, United States
Maryland Hematology & Oncology. P.A.
🇺🇸Silver Spring, Maryland, United States
St. Joseph Mercy Hospital
🇺🇸Ann Arbor, Michigan, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Metro-Minnesota Community Oncology Research Consortium
🇺🇸Saint Louis Park, Minnesota, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana
🇺🇸Billings, Montana, United States
Nebraska Methodist Hospital
🇺🇸Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada - Eastern Avenue
🇺🇸Las Vegas, Nevada, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Rutgers Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
University of New Mexico
🇺🇸Albuquerque, New Mexico, United States
Montefiore Einstein Center for Cancer Care
🇺🇸Bronx, New York, United States
Eastchester Center for Cancer Care
🇺🇸Bronx, New York, United States
National Translational Research Group
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
New York Cancer and Blood Specialists - Setauket Medical Oncology
🇺🇸Port Jefferson Station, New York, United States
Barrett Cancer Center
🇺🇸Cincinnati, Ohio, United States
Oncology Hematology Care Inc
🇺🇸Cincinnati, Ohio, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Consultants in Medical Oncology and Hematology
🇺🇸Broomall, Pennsylvania, United States
Alliance Cancer Specialists
🇺🇸Horsham, Pennsylvania, United States
Virginia Cancer Specialists - Leesburg
🇺🇸Leesburg, Pennsylvania, United States
Cancer Treatment Centers of America
🇺🇸Philadelphia, Pennsylvania, United States
The Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
PRISMA Health - Greenville
🇺🇸Greenville, South Carolina, United States
The West Clinic
🇺🇸Germantown, Tennessee, United States
The Ottawa Hospital - General Campus
🇨🇦Ottawa, Ontario, Canada
St. Jude Children'S Research Hospital
🇺🇸Memphis, Tennessee, United States
Texas Oncology - Central South
🇺🇸Austin, Texas, United States
Mary Crowley Medical Research Center
🇺🇸Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Cook Childrens Medical Center
🇺🇸Fort Worth, Texas, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Texas Oncology- Northeast Texas
🇺🇸Tyler, Texas, United States
Northwest Medical Specialties, PLLC
🇺🇸Tacoma, Washington, United States
Froedtert and The Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Kinghorn Cancer Centre
🇦🇺Darlinghurst, New South Wales, Australia
Sydney Children's Hospital
🇦🇺Randwick, New South Wales, Australia
Royal Darwin Hospital
🇦🇺Tiwi, Northern Territory, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Royal Children's Hospital
🇦🇺Parkville, Victoria, Australia
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
UZ Gent
🇧🇪Gent, Belgium
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Hospital Moinhos de Vento
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital Sírio-Libanês
🇧🇷Sao Paulo, São Paulo, Brazil
Hospital A. C. Camargo
🇧🇷Sao Paulo, São Paulo, Brazil
Clínica Onco Star - Rede D'Or
🇧🇷Sao Paulo, São Paulo, Brazil
BC Cancer ? Vancouver
🇨🇦Vancouver, British Columbia, Canada
London Health Sciences Centre · Victoria Hospital
🇨🇦London, Ontario, Canada
The Hospital for Sick Children
🇨🇦Toronto, Ontario, Canada
Princess Margaret Cancer Center
🇨🇦Toronto, Ontario, Canada
McGill University Health Center
🇨🇦Montreal, Quebec, Canada
Beijing Cancer Hospital
🇨🇳Beijing, China
Beijing Children's Hospital, Capital Medical University
🇨🇳Beijing, China
The First Hospital of Jilin University
🇨🇳Changchun City, China
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
Zhongshan Hospital Fudan Unvierstiy
🇨🇳Shanghai, China
Tianjin Cancer Hospital
🇨🇳Tianjin, China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
🇨🇳Xi'an, China
Aarhus Universitetshospital
🇩🇰Aarhus N, Denmark
Rigshospitalet
🇩🇰København Ø, Denmark
Institut Bergonie
🇫🇷Bordeaux, France
Centre Oscar Lambret
🇫🇷Lille, France
Centre Leon Berard
🇫🇷Lyon, France
Hopital de la Timone
🇫🇷Marseille, France
Institut Universitaire du Cancer de Toulouse-Oncopole
🇫🇷Toulouse, France
Institut de Cancerologie Gustave-Roussy (IGR)
🇫🇷Villejuif, France
Uniklinik Essen
🇩🇪Essen, Germany
Georg-August-Uniklinik
🇩🇪Göttingen, Germany
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
🇩🇪Hamburg, Germany
Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie
🇩🇪Hannover, Germany
SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III
🇩🇪Heilbronn, Germany
Praxis für Hämatologie, Onkologie und Palliativmedizin
🇩🇪Mönchengladbach, Germany
Klinikum der Universität München, Campus Großhadern
🇩🇪München, Germany
Universtitätsklinikum Ulm
🇩🇪Ulm, Germany
Hong Kong Children's Hospital
🇭🇰Hong Kong, Hong Kong
Prince of Wales Hospital
🇭🇰Shatin, Hong Kong
Rambam Health Care Campus
🇮🇱Haifa, Israel
Hadassah University Hospital - Ein Kerem
🇮🇱Jerusalem, Israel
Rabin MC
🇮🇱Petach Tikva, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Sourasky / Ichilov Hospital
🇮🇱Tel Aviv, Israel
Istituto Nazionale Tumori Fondazione G. Pascale
🇮🇹Napoli, Campania, Italy
Ospedale Pediatrico Bambino Gesù - IRCCS
🇮🇹Roma, Lazio, Italy
Policlinico Universitario Agostino Gemelli IRCCS
🇮🇹Roma, Lazio, Italy
Asst Degli Spedali Civili Di Brescia
🇮🇹Brescia, Lombardia, Italy
Irccs Istituto Nazionale Dei Tumori (Int)
🇮🇹Milano, Lombardia, Italy
Istituto Nazionale Tumori di Milano
🇮🇹Milano, Lombardia, Italy
Dipartimento di Scienze Pediatriche Adolescenza
🇮🇹Torino, Piemonte, Italy
Azienda Ospedaliera Meyer
🇮🇹Firenze, Toscana, Italy
Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica
🇮🇹Siena, Toscana, Italy
National Cancer Center Hospital East
🇯🇵Chiba, Japan
Kindai University Hospital
🇯🇵Osaka, Japan
National Cancer Center Hospital
🇯🇵Tokyo, Japan
Seoul National University Bundang Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
Seoul National University Hospital- Adult Site
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital- Pediatric Site
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center- Adult Site
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center- Pediatric Site
🇰🇷Seoul, Korea, Republic of
Auckland City Hospital, Cancer and Blood Research
🇳🇿Auckland, New Zealand
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
🇵🇱Gda?sk, Poland
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
🇵🇱Warszawa, Poland
IPO do Porto
🇵🇹Porto, Portugal
PanOncology Trials
🇵🇷San Juan, Puerto Rico
National University Hospital
🇸🇬Singapore, Singapore
National Cancer Centre
🇸🇬Singapore, Singapore
Medical Oncology Centre of Rosebank
🇿🇦Johannesburg, South Africa
Hospital Sant Joan De Deu
🇪🇸Esplugues De Llobregas, Barcelona, Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
🇪🇸Barcelona, Spain
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
🇪🇸Barcelona, Spain
Hospital Infantil Universitario Nino Jesus
🇪🇸Madrid, Spain
Clinica Universidad de Navarra Madrid
🇪🇸Madrid, Spain
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
START Madrid. Centro Integral Oncologico Clara Campal
🇪🇸Madrid, Spain
Hospital Universitario la Fe
🇪🇸Valencia, Spain
Universitätsspital Basel (USB)
🇨🇭Basel, Switzerland
Ospedale Regionale di Bellinzona Medizin Onkologie
🇨🇭Bellinzona, Switzerland
Inselspital, Klinik und Poliklinik für Medizinische Onkologie
🇨🇭Bern, Switzerland
Unversitätsspital Zürich
🇨🇭Zürich, Switzerland
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei City, Taiwan
Chang Gung Memorial Hospital-Linkou
🇨🇳Taoyuan County, Taiwan
National Taiwan University Hospital
🇨🇳Zhongzheng Dist., Taiwan
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
University College London Hospital
🇬🇧London, United Kingdom
Guys and St Thomas NHS Foundation Trust, Guys Hospital
🇬🇧London, United Kingdom
Royal Manchester Children?s Hospital
🇬🇧Manchester, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom